Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer.

Abstract

Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells was also observed using either 2D or 3D culture systems. VA was cytotoxic for prostate cancer cells but low toxic to normal cells. VA significantly inhibited E2F1/E2F3 expression but increased CASP3 activity. In vivo mouse models further showed its anti-cancer activity and potential property of chemosensitizer with promoting apoptosis. The findings suggest that VA acts as a HDAC3 inhibitor with anti-cancer effect on prostate cancer by regulating E2F1/E2F3/CASP3 axis.

• Authors: Rui Han, Hongxing Yang, Ya Li, Changquan Ling, Lingeng Lu
• Journal: Medical oncology (Northwood, London, England) (Med Oncol) Vol. 39 Issue 12 Pg. 213 (Sep 29 2022) ISSN: 1559-131X [Electronic] United States
• PMID: 36175803 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Histone Deacetylase Inhibitors
• Pentanoic Acids
• Caspase 3
• Histone Deacetylases
• histone deacetylase 3
• n-pentanoic acid

Topics

• Animals
• Caspase 3
• Histone Deacetylase Inhibitors (pharmacology)
• Histone Deacetylases (metabolism)
• Humans
• Male
• Mice
• Pentanoic Acids
• Prostate
• Prostatic Neoplasms (drug therapy)